RP-1664

RP-1664 : Inhibitor of PLK4

Structure

Information

  • PLK4
  • Inhibitor
  • up to 100 nM

In Vitro Validations

No in Vitro Validations

In Cell Validations

In Vivo Data

Off-Target Selectivity Assesments

Potency assay, off target (cells): RP-11664 showed high selectivity across the kinome with significant binding observed with only six of the 274 expressed kinases and confirmed no measurable interaction with AURKA and B. Two of these off-target kinases, FAK and TNK1, were further evaluated using NanoBRET assays to directly determine their selectivity ratios over PLK4. These assays showed that RP-1664 binds PLK4 with 59-fold selectivity over FAK and 3-fold selectivity over TNK1.
Probe Selectivity in Cell:
Kinase binding selectivity was performed at ActivX Biosciences using the Kinativ kinase profiling platform.
I have extra information to add

SERP ratings and comments


SERP Ratings

In Cell Rating
In Model Organisms

SERP Comments:

I do agree with cellular concentrations 2 and 3 however not with cellular concentration 1. 51nM EC50 should be titrated higher than 100nM

(last updated: 28 May 2025 )

SERP Ratings

In Cell Rating
In Model Organisms

SERP Comments:

The compound appears to be selective vs Plk4 and therefore should be suitable for dosing above 100 nM, which only represents 2x above it's cellular IC50. I would anticipate dosing up to at least IC90 / 10x above IC50 to get a meaningful dose response. In the cited publication, the authors describe low doses for the oral and iv PK studies to determine overall PK profiles, btu these doses are unlikely to be adequate for any efficacy studies. The literature suggests doses of 20mg/kg would be more realistic for such studies. From the same publication, I really do not understand the use of chow-dosing in the efficacy study, which gives no robust control over actual dose delivered, and would strongly advocate against this dosing route.

(last updated: 5 Jun 2025 )

SERP Ratings

In Cell Rating
In Model Organisms

(last updated: 5 Jun 2025 )